A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

Trial Profile

A 36-week, Randomized, Double-blind, Multi-center, Parallel Group Study Comparing the Efficacy and Safety of Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Feb 2015

At a glance

  • Drugs Aliskiren (Primary) ; Losartan
  • Indications Essential hypertension; Hypertension; Left ventricular hypertrophy
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ALLAY; ASPIRE-HIGHER
  • Sponsors Novartis
  • Most Recent Events

    • 09 May 2011 Additional trial locations (Argentina, Colombia, Finland, Italy, Russia, Spain, Sweden) added as reported by ClinicalTrials.gov
    • 15 Jun 2009 Pharmcodynamic results presented at the 19th European Meeting on Hypertension, 2009.
    • 03 Feb 2009 Resulted reported in Circulation, 3 February 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top